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background: Dabigatran etexilate, oral direct inhibitors of thrombin, was demonstrated to be as efficacious and safe as warfarin in non-valvular 
atrial fibrillation (AF). However, it remains to be elucidated the usefulness of coagulation test to determine the proper dose of dabigatran to prevent 
cardiogenic embolism and adverse side effects.
methods: We prospectively evaluated the relationship among the background of the patients and the outcome of dabigatran therapy, and 
investigated the clinical usefulness of activated partial thromboplastin time (APTT) to quantify the anti-thrombotic effect and safety. We enrolled 
consequent 129 patients with AF (age 73+1 years, male n=70, CHADS2 score 2.2+0.1) who were prescribed dabigatran from April 2011 to August 
2012, and conducted follow-up study by August 2013. Within 2 weeks of enrollment, blood sampling for APTT measurement was performed 150+7 
minutes after dabigatran taken.
results: Mean dose of dabigatran administered was 224+3 mg/day, which reached APTT of 48+1 sec. APTT did not correlate with age, creatinine 
clearance (CCr), and body mass index (BMI). By the end of follow-up period (Mean 475+21 days), seven of 129 patients (5.4%; age 81+3 years, 
CHADS2 score 3.7+0.2) suffered from ischemic stroke. Multiple logistic regression analysis revealed that CHADS2 score (p< 0.05, Odds ratio 3.9) 
and APTT less than 35 sec (p< 0.05, Odds ratio 42.3) were independent predictors of the occurrence of ischemic stroke. Low BMI was associated 
with both ischemic stroke (p< 0.05, Odds ratio 1.5) and hemorrhagic side effects (p< 0.05, Odds ratio 1.4). Bleeding required cessation of 
dabigatran was observed in 8 patients (6.2%; melena n=5, macrohematuria n=1, subcutaneous bleeding n=2). APTT did not have predictive value 
for hemorrhagic side effects (p=0.92). Neither gender, CCr, nor the duration of AF affected the occurrence of ischemic stroke and hemorrhagic 
complications.
conclusions: Among AF patients who received dabigatran, APTT less than 35 sec, low BMI, and high CHADs2 score were independently predictive of 
ischemic stroke. Fixed point measurement of APTT might be useful to evaluate the anticoagulant effect of dabigatran.
